Hypertriglyceridemia Pipeline Summary

DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypertriglyceridemia: Understanding

Hypertriglyceridemia: Overview

Hypertriglyceridemia is a lipid disorder characterized by elevated fasting serum triglyceride (TG) levels, typically defined as ?150 mg/dL (1.7 mmol/L), with severe hypertriglyceridemia (?500 mg/dL) substantially increasing the risk of acute pancreatitis. The condition may be primary (genetic), resulting from inherited disorders of lipoprotein metabolism, or secondary to obesity, type 2 diabetes mellitus, metabolic syndrome, excessive alcohol intake, chronic kidney disease, hypothyroidism, pregnancy, or medications such as corticosteroids and estrogens. Mild to moderate hypertriglyceridemia is often asymptomatic but is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Patients with markedly elevated triglyceride levels may develop eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, or recurrent episodes of acute pancreatitis characterized by severe abdominal pain, nausea, and vomiting. Hypertriglyceridemia is a common metabolic disorder requiring early recognition and comprehensive cardiovascular risk management.

The pathophysiology of hypertriglyceridemia involves increased production and/or impaired clearance of triglyceride-rich lipoproteins, including very-low-density lipoproteins (VLDL) and chylomicrons. Genetic variants affecting lipoprotein lipase (LPL), APOC2, APOA5, GPIHBP1, LMF1, or APOE, together with insulin resistance, obesity, and hepatic overproduction of VLDL, contribute to triglyceride accumulation in the circulation. Elevated triglyceride-rich lipoprotein remnants promote endothelial dysfunction, vascular inflammation, and atherogenesis, while extreme triglyceride elevations increase pancreatic capillary injury through release of toxic free fatty acids, predisposing to acute pancreatitis.

Diagnosis is based on a fasting lipid profile, supported by evaluation for secondary causes through assessment of glucose metabolism, thyroid function, liver and renal function, medication history, and family history. Additional investigations, including apolipoprotein B measurement or genetic testing, may be considered in selected patients with suspected inherited lipid disorders.

Management of hypertriglyceridemia focuses on reducing triglyceride levels, preventing pancreatitis, and lowering cardiovascular risk through lifestyle modification and pharmacological therapy. First-line treatment includes weight reduction, regular physical activity, restriction of refined carbohydrates and alcohol, adoption of a heart-healthy diet, and optimal management of diabetes and other secondary causes. Statins remain the primary therapy for patients with elevated ASCVD risk, while fibrates, high-dose prescription omega-3 fatty acids (including icosapent ethyl in appropriate patients), and niacin may be used in selected individuals, particularly those with severe hypertriglyceridemia. Patients with triglyceride levels ?500–1,000 mg/dL require prompt intervention to reduce pancreatitis risk, and emerging therapies targeting apolipoprotein C-III (APOC3) and angiopoietin-like protein 3 (ANGPTL3) have demonstrated substantial triglyceride lowering in clinical trials. Long-term monitoring of lipid levels and comprehensive cardiovascular risk factor management remain essential components of care.

"Hypertriglyceridemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs

DR10624: Doer Biologics

DR10624 is an investigational long-acting Fc fusion protein tri-agonist that simultaneously activates the FGF21 receptor, GLP-1 receptor, and glucagon receptor to improve lipid and metabolic regulation. It is being evaluated as a once-weekly subcutaneous injection for the treatment of severe hypertriglyceridemia in patients receiving stable background lipid-modifying therapy. In the ongoing Phase III, randomized, double-blind, placebo-controlled trial, the study is assessing the efficacy and safety of DR10624, with the primary endpoint being the percentage reduction in fasting triglyceride levels at Week 26.

SEFA-1024: NorthSea Therapeutics

SEFA-1024 is an oral, gut/liver targeted, semi-synthetic eicosapentaenoic acid derivative in development for the treatment of severe hypertriglyceridemia (sHTG). sHTG significantly increases the risk of acute pancreatitis a may increase cardiovascular event risk. There is a significant unmet medical need due to inadequate efficacy of existing therapies on TG, non-HDL-C, and glycemic control. Based on extensive pre-clinical data from a translatable model of human HTG, SEFA-1024 has the potential to address the unmet needs in treating sHTG. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Hypertriglyceridemia.

GC304: Genecradle Therapeutics

GC304 adeno-associated virus injection is a recombinant AAV viral vector carrying the LPL gene expression cassette. LPL is a key enzyme in the human body for hydrolyzing plasma-rich lipoprotein triglycerides. GC304 injection, through the efficient expression of the artificially optimized LPLS447X gene, a natural beneficial mutant of LPL, in the human body, can degrade triglycerides in circulating blood over the long term and efficiently, providing a new type of gene drug for the prevention and/or treatment of severe hypertriglyceridemia. Currently, the drug is in Phase I stage of its clinical trial for the treatment of hypertriglyceridemia.

Further product details are provided in the report……..

Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hypertriglyceridemia
• There are approx. 18+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. Phase III include, Doer Biologics.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights

• Hypertriglyceridemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypertriglyceridemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypertriglyceridemia drugs?
• How many Hypertriglyceridemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypertriglyceridemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zhejiang Doer Biologics
• NorthSea Therapeutics
• Arrowhead Pharmaceuticals
• GeneCradle
• MediciNova
• CorrectSequence Therapeutics
• Sunho (China) BioPharmaceutical
• Shanghai JMT-Bio Inc.
• OrsoBio
• Marea Therapeutics
• Ionis Pharmaceuticals
• Kylonova (Xiamen) Biopharma

Key Products

• DR10624
• NST-1024
• Plozasiran
• GC304
• MN-001
• CS-121
• ISH0688
• JMT202
• TLC-2716
• MAR001
• ION775
• Kylo-12